DAPA - Egypt Study

Trial Identifier: D1690R00049
Sponsor: AstraZeneca
NCTID:: NCT03624803
Start Date: March 2019
Primary Completion Date: March 2020
Study Completion Date: March 2020

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
Egypt, Egypt Alexandria, Egypt, Egypt, D1690R00049
Egypt, Egypt Assuit, Egypt, Egypt, D1690R00049
Egypt, Egypt Behira, Egypt, Egypt, D1690R00050
Egypt, Egypt Cairo, Egypt, Egypt, D1690R00053
Egypt, Egypt Dokki, Egypt, Egypt, D1690R00049
Egypt, Egypt El Rehab, Egypt, Egypt, D1690R00049
Egypt, Egypt Fiasal, Egypt, Egypt, D1690R00049
Egypt, Egypt Giza, Egypt, Egypt, D1690R00049
Egypt, Egypt Haram, Egypt, Egypt, D1690R00049
Egypt, Egypt Heliopolis, Egypt, Egypt, D1690R00049
Egypt, Egypt Maadi, Egypt, Egypt, D1690R00049
Egypt, Egypt Manial, Egypt, Egypt, D1690R00049
Egypt, Egypt Mansoura, Egypt, Egypt, D1690R00051
Egypt, Egypt Mansoura, Egypt, Egypt, D1690R00049
Egypt, Egypt Mohandesin, Egypt, Egypt, D1690R00049
Egypt, Egypt Mohandessin, Egypt, Egypt, D1690R00049
Egypt, Egypt Nasr city, Egypt, Egypt, D1690R00049
Egypt, Egypt Nasr City, Egypt, Egypt, D1690R00049
Egypt, Egypt Nozha, Egypt, Egypt, D1690R00049
Egypt, Egypt Port Said, Egypt, Egypt, D1690R00052
Egypt, Egypt Sharkia, Egypt, Egypt, D1690R00049
Egypt, Egypt Sohag, Egypt, Egypt, D1690R00049
Egypt, Egypt Tanta, Egypt, Egypt, D1690R00049
Egypt, Egypt West lbalad, Egypt, Egypt, D1690R00049